



Affiliated to International Society of Addiction Medicine

# 13<sup>th</sup> European Congress Heroin Addiction & Related Clinical Problems

European Opiate Addiction Treatment Association - EUROPAD



## 25-27 May 2018

Jagiellonian University

# KRAKOW POLAND-EU



Under the co-patronage of  
Santa Chiara University Hospital, Pisa, Italy, EU





## EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

### The vision

EUROPAD exists to improve the lives of opiate misusers and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opiate addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide

## Scientific Committee of the 13th Congress

### Coordinators

Icro Maremmani (Pisa, Italy)  
Marc Reisinger (Brussels, Belgium)

Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)  
Andrej Kastelic (Ljubljana, Slovenia)

### Local Scientific Committee

Tadeusz Marek (Krakow, Poland)  
Irena Roterman-Konieczna (Krakow, Poland)

Marcin Ziólkowski (Bydgoszcz, Poland)  
Piotr Gałeczki (Łódź, Poland)

### International Scientific Committee

Adrian-Octavian Abagiu (Bucarest, Romania)  
Hannu Alho (Helsinki, Finland)  
Marc Auriacombe (Bordeaux, France)  
Michael Farrell (Sydney, New South Wales, Australia)  
Loretta Finnegan (Satellite Beach, Florida, USA)  
Gabriele Fischer (Vienna, Austria)  
Gilberto Gerra (UNODC)  
Milazim Gjocjaj (Pristina, Kosovo)  
Liljana Ignjatova (Skopje, Macedonia)  
Ante Ivancic (Porec, Croatia)  
Minja Jovanovic (Kragujevac, Serbia)  
Alexander Kantchelov (Sofia, Bulgaria)  
Mercedes Lovrecic (Ljubljana, Slovenia)  
Angelo G. I. Maremmani (Viareggio, Italy)  
Garrett McGovern (Dublin, Ireland)

Genci Mucullari (Tirana, Albania)  
Lubomir Okruhlica (Bratislava, Slovak Republic)  
Mark Parrino (New York, New York, USA)  
Luis Patricio (Lisbon, Portugal)  
Einal Peles (Tel Aviv, Israel)  
Giulio Perugi (Pisa, Italy)  
Jens Reimer (Hamburg, Germany)  
Marta Torrens (Barcelona, Spain)  
Didier Touzeau (Bagneux France)  
Ambros Uchtenhagen (Zurich, Switzerland)  
Albrecht Ulmer (Stuttgart, Germany)  
Peter Vossenberg (Deventer, The Netherlands)  
Helge Waal (Oslo, Norway)  
Stephan Walcher (Munich, Germany)  
George Woody (Philadelphia, Pennsylvania, USA)

*Under the Patronage of*

**World Federation for the Treatment of Opioid Dependence, New York, NY, USA**  
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

**Jagiellonian University, Krakow, Poland**

**Santa Chiara University Hospital, Pisa, Italy**

*Promoted by*

**European Opiate Addiction Treatment Association**

**Association for the Application of Neuroscientific Knowledge to Social Aims, Lucca, Italy**

***Congress Presidents***

EDWARD JACEK GORZELANCZYK (Bydgoszcz, Poland)

ICRO MAREMMANI (Pisa, Italy)

***Local Scientific Committee***

Marcin Ziótkowski -Bydgoszcz, Poland

Piotr Gałeczki - Łódź, Poland

Tadeusz Marek - Krakow, Poland

Irena Roterman-Konieczna - Krakow, Poland

***Venue***

Jagiellonian University

16 Sw. Lazarza Str. PL 31-530 Kraków, Poland

Phone: +48 12 619-96-02

[http://www.cdk.wl.uj.edu.pl/en\\_GB/](http://www.cdk.wl.uj.edu.pl/en_GB/)

***Organizing Committee***

Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy

Phone +39 0564412038 - Fax +39 0564412485

E-mail: [giusi@tigicongress.com](mailto:giusi@tigicongress.com)

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy

Phone +39 0584790073 - Fax +39 058472081

E-mail: [info@aucns.org](mailto:info@aucns.org)



Room and time ABSTRACT No

## PROGRAM

### FRIDAY MAY 25, 2018

#### SELECTED ORAL PRESENTATIONS

Room A	<b>Europad Selected Presentations</b> <i>Chair: Angelo G.I. Maremmi (Viareggio, Italy, EU) - Matteo Pacini (Pisa, Italy, EU)</i>	
12:00	SOP-01	ADRIAN O. ABAGIU (Bucarest, Romania, EU) - 5 years of methadone maintenance treatment in arena OMT center-Bucharest
12:20	SOP-02	OLAV DALGARD (Oslo, Norway) - Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies
12:40	SOP-03	OLAV DALGARD (Oslo, Norway) - Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injecting drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
13:00	SOP-04	ALICE DESCHENAU (Villejuif, France, EU) - Addict Assist: a study about acceptability of a questionnaire to assess substance use troubles in a French psychiatric hospital
13:20	SOP-05	FELICIA HEIDEBRECHT (London, UK) - Predictors of poor health and heroin use in methadone-treated injecting heroin users: The importance of methadone dosage and crack cocaine use
13:40	SOP-06	BODIL MONWELL (Jönköping, Sweden, EU) - Opiates versus other opioids - are these relevant diagnostics?
14:00	SOP-07	EINAT PELES (Tel Aviv, Israel) - Cannabis use is associated with worse methadone maintenance treatment outcome but not among schizophrenia and other psychotic patients
14:20	SOP-08	OMRI SINAI (Tel Aviv, Israel) - Induced delusional disorder among opiate users: A case report
14:40	SOP-09	JAMIE WILLIAMS (Providence, Rhode Island, USA) - Clinical and psychological interventions in heroin addiction. Spiritual approach for the treatment of opioid addiction
15:00	SOP-10	JULIA FEIT (Bydgoszcz, Poland, EU) - Disturbances of eyeballs movements in HIV positive and HIV negative opioid addicted individuals before and after the administration of therapeutic dose of methadone

## FRIDAY MAY 25, 2018

11:00	<b>PRE-CONFERENCE SYMPOSIA</b>	
Plenary Room	<b>1 - Pain management and addicton</b> <i>Chair: Wojciech Leppert (Poznań, Poland, EU)</i>	
11:00	PCS01-1	ANNA PRZEKLASA-MUSZYŃSKA (Krakow, Poland, EU) - The current role of cannabinoids in the treatment of chronic pain
11:30	PCS01-2	MAGDALENA KOCOT-KĘPSKA (Krakow, Poland, EU) - Acute pain treatment in opioid tolerant patients
12:00	PCS01-3	RYSZARD PRZEWŁOCKI (Krakow, Poland, EU) - Neurobiology of opioid addiction
12:30	PCS01-4	WOJCIECH LEPPERT (Poznań, Poland, EU) - New possibilities of chronic pain management
<b>SPECIAL EVENT funded by TBC</b>		
<b>Title to be confirmed</b> <i>Chair: Author Name and Surname (City, Country)</i>		
13:00	SE01-1	AUTHOR NAME AND SURNAME (City, Country) - Title to be confirmed
13:30	SE01-2	AUTHOR NAME AND SURNAME (City, Country) - Title to be confirmed
14:00	SE01-3	AUTHOR NAME AND SURNAME (City, Country) - Title to be confirmed
<b>SPECIAL EVENT funded by TBC</b>		
Plenary Room	<b>POP UP Meeting</b> <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>	
14:30	SE02-1	Brain storming open to all speakers regarding the future of Opioid Dependence Treatment
<b>SPECIAL EVENT funded by Molteni</b>		
<b>Practicability, safety, and efficacy of oral levo-methadone in the treatment of Opioid Addiction</b> <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>		
15:30	SE03-1	STEPHAN WALCHER (Munich, Germany, EU) - Title to be confirmed
16:00	SE03-2	ANGELO G.I. MAREMMANI (Viareggio, Italy, EU) - Title to be confirmed
16:30	SE03-3	MARCO RIGLIETTA (Bergamo, Italy, EU) - Title to be confirmed

Room ABSTRACT  
and time No


## FRIDAY MAY 25, 2018

Plenary  
Room


### PLENARY SESSION

Chair: *Icro Maremmanni (Pisa, Italy, EU)*  
*Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)*

17:15	PS1	ICRO MAREMMANI (Pisa, Italy, EU) & EDWARD J. GORZELANCZYK (Bydgoszcz, Poland, EU) - Conference Opening
17:30	PS2	MARK PARRINO (New York, NY, USA) - Policy and political dynamics of the opioid addiction crisis in the United States
18:00	PS3	MAURICE DEMATTEIS (Grenoble, France, EU) - Agonist opioid therapeutic strategies: Which treatment for which patients?
19:00	PS4	LORETTA FINNEGAN (Avalon, NJ, USA) - "You've come a long way baby!" Neonatal Abstinence Syndrome and progress over 5 decades
20:00		BREAK
20:30		<b>WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2018 - THE ALESSANDRO TAGLIAMONTE AWARD</b>
	<b>TO BE AWARDED:</b>	MAURICE DEMATTEIS (Grenoble, France, EU) MATTEO PACINI (Pisa, Italy, EU) GABRIELLE WELLE-STRAND (Oslo, Norway)
	<b>CAREER AWARD:</b>	MARK PARRINO (New York, NY, USA)



**CHIMERA AWARD**  
European Opiate Addiction Treatment Association Award  
"The Alessandro Tagliamonte Award"



**"Dedicated to all those who dream of a better world for drug addicts"**

#### FORMER RECIPIENTS:

Marc Auriacombe (France) - 2002  
Olof Blix (Sweden) - 2000  
Miguel Casas (Spain) - 2012  
Thomas Clausen (Norway) - 2014  
Pascal Courty (France) - 2012  
Jean-Jacques Deglon (Switzerland) - 2004  
Sergey Dvoryak (Ukraine) - 2010  
Gabriele Fischer (Austria) - 2008  
Gilberto Gerra (Italy) - 2006  
Ante Ivancic (Croatia) - 2006  
Alexander Kantchelov (Bulgaria) - 2004  
Andrej Kastelic (Slovenia) - 2008  
Mercedes Lovrecic (Slovenia) - 2002

Vladimir Mendelevich (Russia) - 2014  
Lubomir Okruhlica (Slovak Republic) - 2002  
Pier Paolo Pani (Italy) - 2004  
Luis Patricio (Portugal) - 2010  
Einat Peles (Israel) - 2016  
Slavko Sakoman (Croatia) - 2010  
Lorenzo Somaini (Italy) - 2014  
Marta Torrens (Spain) - 2006  
Didier Touzeau (France) - 2008  
Ambros Uchtenhagen (Switzerland) - 2016  
Peter Vossenbergh (The Netherlands) - 2016  
Helge Waal (Norway) - 2012

#### FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - 2016  
Loretta Finnegan (USA) - 2010  
Mary Jeanne Kreek (USA) - 2014  
Joyce Lowinson (USA) - 2007

Icro Maremmanni (Italy) - 2004  
Robert Newman (USA) - 2012  
Marc Reisinger (Belgium) - 2004  
Alessandro Tagliamonte (Italy) - 2004

Room and time	ABSTRACT No	
<b>SATURDAY MAY 26, 2018</b>		
Plenary Room	<b>PLENARY SESSION</b> <i>Chair: Marc Reisinger (Brussels, Belgium, EU)</i> <i>Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>	
9:00	PS5	MARC AURIACOMBE (Bordeaux, France, EU) - Title tbc
10:00	COFFEE BREAK	
10:30	<b>PARALLEL SYMPOSIA</b>	
Plenary Room	<b>1 - Prisoners with substance use disorder and other co-morbidities – medical and human rights considerations</b> <i>Chair: Gabriele Fischer (Vienna, Austria, EU) - Marta Torrens (Barcelona, Spain, EU)</i>	
10:30	S01-1	DAGMAR HEDRICH (Lissabon, Portugal, EU) - Opioid maintenance in European prisons: Is the treatment gap closing ? – From a European Perspective
11:00	S01-2	PETER KASTNER (Vienna, Austria, EU) - OPCAT Mandate in Europe highlighting results from Austria in improving accessibility to medical care for prisoners under the legal mandate (2012-2017)
11:30	S01-3	MARI AMOS (Tallin, Estonia, EU) - Preventive Human Rights Protection for prisoners in health issues – an international perspective
12:00	S01-4	ROCIO MARTIN-SANTOS (Barcelona, Spain, EU) - Cost effectiveness and management of hepatitis C treatment in patients with substance use disorder
Room A	<b>2 - Expanding access to buprenorphine treatment</b> <i>Chair: Christopher Welsh (Baltimore, MD, USA)</i>	
10:30	S02-1	YNGVILD OLSEN (Baltimore, MD, USA) - Overview of the problem and structural obstacles to implementing change
11:00	S02-2	ERIC WEINTRAUB (Baltimore, MD, USA) - TELE-BUP: prescribing buprenorphine to patients in underserved areas using tele-medicine
11:30	S02-3	CHRISTOPHER WELSH (Baltimore, MD, USA) - Initiating buprenorphine from the emergency department or hospital: capitalizing on the window of opportunity
12:00	S02-4	AARON GREENBLATT (Baltimore, MD, USA) - Telephone consultation to primary care providers: trying to increase prescriber comfort
Room B	<b>3 - Opioid addiction mechanisms</b> <i>Chair: Wojciech Solecki (Krakow, Poland, EU)</i>	
10:30	S03-1	WOJCIECH SOLECKI (Krakow, Poland, EU) - Behavioral and molecular endophenotypes of opioid addiction
11:00	S03-2	MICHAŁ KIEŁBIŃSKI (Krakow, Poland, EU) - Ventral tegmental area regulation of cocaine and oxycodone craving
11:30	S03-3	ADAM HAMED (Warsaw, Poland, EU) - Serotonin and glutamate co-transmission in reward anticipation measured by 50-khz ultrasonic vocalization in morphine conditioned context
12:00	S03-4	KAROLINA KARWOWSKA (KRAKOW, POLAND, EU) - Motivational and physiological symptoms of morphine physical dependence - role of adrenergic and corticoid receptor mechanisms



Room and time	ABSTRACT No	<b>SPECIAL EVENT funded by Camurus</b>
Plenary Room		<b>Achieving best outcomes in OUD care. Current challenges, future trends</b> <i>Chair: Gabriele Fischer (Vienna, Austria, EU)</i>
12:30	SE04-1	MIKAEL SANDELL (Stockholm, Sweden, EU) - What is "standard of care in opioid use disorder?" How to achieve this?
12:45	SE04-2	MAURICE DEMATTEIS (Grenoble, France, EU) - Making treatment work in OUD: Practical choices for individuals. What matters must
13:00	SE04-3	JENS REIMER (Bremen, Germany, EU) - Challenges to achieving best outcomes in OUD care. Where are the gaps, what are solutions now and in the future
13:15	SE04-4	Congress Debate: How should we prepare for the future of OUD care?
13:30		CONFERENCE LUNCH
14:30		<b>PARALLEL SYMPOSIA - SATURDAY MAY 26, 2018</b>
Plenary Room		<b>4 - Continuity of treatment in Israel</b> <i>Chair: Suzan Ben Ezra (Jerusalem, Israel)</i>
14:30	S04-1	ARTURO G. LERNER (Natania, Israel) - Ayahuasca in the treatment and harm reduction of substance use disorder- Mechanism of action and clinical aspects
15:00	S04-2	SHIRLEY HERTZ-KEISAR (Ness Ziona, Israel) - The new Dual Disorders division – System in progress
15:30	S04-3	ILAN TAL, (Tel Aviv, Israel) - Multi-disciplinary model for prescription opioids misuse in private setting
16:00	S04-4	MICHAEL AMNON (Haifa, Israel) - The connection between resilience and craving among inpatient programs
Room A		<b>5 - Novel psychoactive substances: psychiatric consequences and related behavioural addictions</b> <i>Chair: Rok Tavcar (Ljubljana, Slovenia, EU)</i>
14:30	S05-1	ROK TAVCAR (Ljubljana, Slovenia, EU) - Novel psychoactive substances: what every clinician needs to know about
15:00	S05-2	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Novel synthetic cannabinoids: lessons learned
15:30	S05-3	BARBARA LOVRECIC (Ljubljana, Slovenia, EU) - Novel synthetic cathinones: lessons learned
16:00	S05-4	MOJCA ZVEZDANA DERNOVSEK (Ljubljana, Slovenia, EU) - Assessing, treatment and clinical management of psychiatric consequences of novel psychoactive substances use and related behavioural addictions
Room B		<b>6 - Addictive Disorders: Pre-existing factors and specific psychopathology</b> <i>Chair: Icro Maremmanni (Pisa, Italy, EU)</i>
14:30	S06-1	IACOPO BELCARI (Pisa, Italy, EU) - Are personality disorders pre-existing factors of addictive behaviour?
15:00	S06-2	LUCA ROVAI (Pisa, Italy, EU) - Are affective temperaments pre-existing factors of addictive behaviour?
15:30	S06-3	ANGELO G.I. MAREMMANI (Pisa, Italy, EU) - Towards a specific psychopathology of Substance Use Disorders
16:00	S06-4	ICRO MAREMMANI (Pisa, Italy, EU) - Should emotional responses to life events be included in the specific psychopathology of Substance Use Disorders?
16:30		COFFEE BREAK

Room and time	ABSTRACT No	
17:00		<b>PARALLEL SYMPOSIA, SATURDAY MAY 26, 2018</b>
Plenary Room	ABSTRACT No	<b>7 - Supporting recovery and normalizing life of people in OAT programmes</b> <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU) - Liljana Ignatova (Skopje, Macedonia)</i>
17:00	S07-1	LILJANA IGNJATOVA (Skopje, Macedonia) - Stigma and secrecy coping in individuals in treatment for substance dependence in Macedonia and Slovenia
17:30	S07-2	NUSA SEGREC (Ljubljana, Slovenia, EU) - Reducing discrimination - treating difficult to reach populations with mental health and substance use disorders
18:00	S07-3	MIRA DELIC (Ljubljana, Slovenia, EU) - Employability of patients with opioid addiction
18:30	S07-4	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Ability for driving of people in AOT programmes
Room A		<b>8 - Hot topics in Heroin Use Disorder patients</b> <i>Chair: Thomas Clausen (Oslo, Norway)</i>
17:00	S08-1	EINAT PELES (Tel Aviv, Israel) - Can a measure of heart rate variability serve as a marker for stress among patients in methadone maintenance treatment (MMT)?
17:30	S08-2	MARC REISINGER (Brussels, Belgium, EU) - Opiate addiction treatment and free movement in the Schengen Area : A complaint against Norway
18:00	S08-3	GABRIELLE K. WELLE-STRAND (Oslo, Norway) - How do mothers/parents in opioid maintenance treatment (OMT) do 8-12 years after their child was born?
18:30	S08-4	THOMAS CLAUSEN (Oslo, Norway) - The use of non-prescribed benzodiazepines and/or amphetamines predict treatment instability in opioid maintenance treatment
Room B		<b>9 - Harm reduction in Israel policy, programs and research</b> <i>Chair: Hgal Brosh (Jerusalem, Israel)</i>
17:00	S09-1	SUZAN BEN EZRA (Jerusalem, Israel) - "A thousand-mile journey begins with one step" - a "first step" for drug and alcohol addicts
17:30	S09-2	HAIM MELL (Afula, Israel) - HIV outbreak related to injection of new psychoactive substances in Tel Aviv, Israel
18:00	S09-3	HAGIT BONNY-NOACH (Ariel, Israel) - Injecting drug use, sex work and differential harm reduction approaches for women: ethnographic study in Israel's largest open drug scene
18:30	S09-4	PAOLA ROSKA (Jerusalem, Israel) - Infectious diseases among OMT patients in Israel - results of a historical cohort study and the new treatment policy
Break-out Room	ABSTRACT No	<b>9B - Multicenter study on opioid misuse before entering Agonist Opioid Treatment in Europe (in collaboration with RADAR system)</b> <i>Chair: Karin McBride (Denver, CO, USA)</i>
19:00	S07-5	Group meeting (by invitation only)
20:45		SPEAKERS' DINNER* Restaurant tbc - Krakow, Poland, EU
		* Tickets are available for all delegates

Room and time	ABSTRACT No	
<b>SUNDAY MAY 27, 2018</b>		
Plenary Room		<b>PLENARY SESSION</b> <i>Chair: Andrej Kastelic (Ljubljana, Slovenia)</i> <i>Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>
9:00	P05	LORENZO SOMAINI (Biella, Italy, EU) - Buprenorphine depot formulation: effective treatment of opioid dependence or only a possibility of minimising risks of illicit diversion or patient non-compliance?
10:00		<b>PARALLEL SYMPOSIA</b>
Plenary Room		<b>10 - Hot topics in Heroin Use Disorder patients</b> <i>Chair: Edward Jacek Gorzelańczyk (Bydgoszcz, Poland, EU)</i>
10:00	S10-1	AYMAN MOHSEN FAREED (Dahlonaga, GA, USA) - The opioid overdose epidemic in the United States and the utilization of intranasal naloxone to reverse it
10:30	S10-2	EDWARD JACEK GORZELAŃCZYK (Bydgoszcz, Poland, EU) - Addiction and dual diagnosis in perspective of cortico-subcortical loop function
11:00	S10-3	HENRY LOTHANE (New York, NY, USA) - Addiction and humanistic treatment goals
11:30	S10-4	JOLANTA B. ZAWILSKA (Lodz, Poland, EU) - Novel psychoactive substances – new players in the old drama
Room A		<b>11 - Hot topics in Heroin Use Disorder patients</b> <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i>
10:00	S11-1	FRANCINA FONSECA (Barcelona, Spain, EU) - Benzodiazepines use “to get high” in patients admitted for addiction treatment in Spain
10:30	S11-2	MARTIN HARALDSEN (Larvik, Norway) - Agonist opioid treatment (AOT) with buprenorphine (BPN) and often benzodiazepine (BZD) in the GP-setting: Enabling a normalized life
11:00	S11-3	ALEXANDER KANTCHELOV (Sofia, Bulgaria, EU) - The reverse tolerance effect in methadone treated patients
11:30	S11-4	MATTEO PACINI (Pisa, Italy, EU) - Benzodiazepine Use Disorder in patients with and without Opioid Use Disorder
Room B		<b>12 - A new way to think about Dual Disorders: Opioid System and Mental Disorders in collaboration with World Association on Dual Disorder (WADD)</b> <i>Chair: Miguel Casas (Barcelona, Spain, EU)</i>
10:00	S12-1	NESTOR SZERMAN (Madrid, Spain, EU) - Opioid system and Mental Disorders
10:30	S12-2	MARTA TORRENS (Barcelona, Spain, EU) - Mood Disorders and Opioid Use Disorder
11:00	S12-3	CARLOS RONCERO (Barcelona, Spain, EU) - Psychosis and Opioid system
11:30	S12-4	ICRO MAREMMANI (Pisa, Italy, EU) - How to manage Benzodiazepines Use Disorder during methadone treatment

Room and time	ABSTRACT No	
12:00		<b>PARALLEL SYMPOSIA, SUNDAY MAY 27, 2018</b>
Plenary Room	ABSTRACT No	<b>13 - Psychological therapies and interventions in the treatment of opiate use disorder</b> <i>Chair: Alexander Kantchelov (Sofia, Bulgaria, EU)</i>
12:00	S13-1	PAUL DELANEY (Dublin, Ireland, EU) - Why a willingness to change is often not sufficient – utilizing motivational interviewing to develop self-efficacy and confidence to change
12:30	S13-2	ALBRECHT ULMER (Stuttgart, Germany, EU) - How to touch the souls of our addicted patients better
13:00	S13-3	ALEXANDER BELCHEV (London, UK) - Integrative therapeutic model of recovery network Turning Point South London, UK
13:30	S13-4	CAROLINE NORMAN (London, UK) - Attachment theory and open dialogue in addictions: How can mentalizing help?
Room A		<b>14 - Hot topics in Substance Use Disorder patients</b> <i>in collaboration with International Society of Addiction Medicine (ISAM)</i> <i>Chair: Riaz Khan (Geneva, Switzerland)</i>
12:00	S14-1	RIAZ KHAN (Geneva, Switzerland) - Public health approach as the basis for addiction policy; the Swiss report on the challenge of addictions
12:30	S14-2	CHRISTOS KOUIMTSIDIS (London, UK) - Could and should cognitive behaviour models being applied across substance misuse groups; are there more differences than commonalities?
13:00	S14-3	ICRO MAREMMANI (Pisa, Italy, EU) - How to manage alcohol use disorder during methadone treatment
13:30	S14-4	LORENZO SOMAINI (Biella, Italy, EU) - <b>Tbc</b>
Room B		<b>15 - Title</b> <i>Chair: Marc Auriacombe (Bordeaux, France, EU)</i>
12:00	S15-1	MARC AURIACOMBE (Bordeaux, France, EU) - <b>Tbc</b>
12:30	S15-2	AMINE BENYAMINA (Villejuif, France, EU) - <b>Tbc</b>
13:00	S15-3	JEAN-PIERRE DAULOUEDE (Bayonne, France, EU) - <b>Tbc</b>
13:30	S15-4	DIDIER TOUZEAU (Bagneux, France, EU) - How to prevent misuse of opioid treatment?
14:00	PL1c	ICRO MAREMMANI (Pisa, Italy, EU) - Conference Closing and Arrivederci ..... a ..... Lisbon, Portugal, May 26-28, 2020

**POSTER SESSION**

ABSTRACT No	
P-01	SONILA BITRI TIVARI (Tirana, Albania) - Are we missing substance use disorders diagnosis in the emergency department ?
P-02	SONILA BITRI TIVARI (Tirana, Albania) - Alcohol use disorder and heroin addiction. What are the challenges?
P-03	MANUELE GLAUCO CARBONE (Pisa, Italy, EU) - The SCL90-based psychopathological structure may be applied in substance use disorder patients irrespectively of the involved drug also in heroin, alcohol and cocaine mono-drug users
P-04	FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Further evidence of a psychopathology specific to Heroin Use Disorder. Relationships between psychopathological dimensions and addictive behaviours
P-05	MAURICE DEMATTEIS (Grenoble, France, EU) - Prevalence of opioid misuse in chronic opioid analgesic therapy for non-cancer pain is high in France
P-06	FELICIA HEIDEBRECHT (London, UK) - Practitioners' experiences of working with dual users of heroin and crack cocaine. A thematic analysis
P-07	FELICIA HEIDEBRECHT (London, UK) - Differences in treatment outcomes by frequency and drug preference for dual users of heroin and crack in opiate substitution therapy - A pilot study
P-08	DUNCAN HILL (Lanarkshire, UK) - Characteristics of the "revolving door" patients enrolling in the opioid dependence treatment in the EUROPAD - RADARs surveillance initiative
P-09	DUNCAN HILL (Lanarkshire, UK) - Reported gabapentin and pregabalin use by patient enrolling in the opioid dependence treatment in the EUROPAD - RADARs surveillance initiative
P-10	MARION JOUHANNEAU (Villeneuve les Maguelone, France, EU) - Inventory of opiates addiction treatment (OAT) in prisons in France in 2017
P-11	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Excess suicide mortality in Heroin Use Disorder patients seeking Opioid Agonist Treatment in Slovenia and risk factors for suicide
P-12	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Capgras syndrome in a heroin addict. A case study
P-13	SORAYA MAYET (Hull, England, UK) - Effectiveness of opioid overdose and take-home naloxone training for staff
P-14	FADI MEROUEH (Villeneuve les Maguelone, France, EU) - The use of suboxone (buprenorphine and naloxone) in prison
P-15	HEATHER A. OLSEN (Denver, CO, USA) - Comparing prescription opioid use among heroin users using the RADARS® System EUROPAD program
P-16	PASQUALINA ROCCO (Marca Trevigiana, Italy, EU) - Attention Deficit Hyperactivity Disorder in Heroin Use Disorder patients
P-17	ANAT SASON (Tel Aviv, Israel) - Nutrition intervention among methadone maintenance treatment (MMT) patients and food addiction



## Faculty

Adrian O. ABAGIU	National Institute for Infectious Diseases Prof Dr. Matei Bals (NIIDMB), Bucarest, Romania, EU - [E-Mail: adyaba@gmail.com]
Michael AMNON	Haifa University, Haifa, Israel - [E-Mail: haderech@netvision.net.il]
Mari AMOS	UN Subcommittee on Prevention of Torture, Tallin, Estonia, EU - [E-Mail: mari.amos@gmx.com]
Marc AURIACOMBE	Centre Hospitalier Charles Perrens - Pôle Addictologie - Bordeaux, France, EU - [E-Mail: marc.auriacombe@u-bordeaux.fr]
Iacopo BELCARI	Vincent P. Dole Dual Diagnosis Unit, Department of Specialty Medicine, Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: iacopo.belcari@gmail.com]
Alexander BELCHEV	Turning Point South London, London, UK - [E-Mail: albelchev@gmail.com]
Amine BENYAMINA	Unité d'addictologie de l'hôpital Paul Brousse, Villejuif, France, EU - [E-Mail: abenyamina13@gmail.com]
Sonila BITRI TIVARI	Department of Clinical Toxicology and Addiction, American Hospital, Tirana, Albania - [E-Mail: sonila_bitri@yahoo.com]
Hagit BONNY-NOACH	Ariel University, Ariel, Israel - [E-Mail: hagitbo@gmail.com]
Manuele Glauco CARBONE	School of Psychiatry, University of Pisa, Italy, EU - [E-Mail: manuelglauco carbone@gmail.com]
Thomas CLAUSEN	Norwegian Centre for Addiction Research (SERAF), University of Oslo, Norway - [E-Mail: thomas.clausen@medisin.uio.no]
Olav DALGARD	Akershus University, Oslo, Norway - [E-Mail: ece.kucuksayrac@gilead.com]
Jean-Pierre DAULOUEDE	Centre Hospitalier de la Côte Basque, Bayonne, France, EU - [E-Mail: jeanpierredaulouede@gmail.com]
Paul DELANEY	coAim Sky Business Centre, Dublin, Ireland - [E-Mail: pdelaney3@gmail.com]
Mira DELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana - [E-Mail: mirjanadelic@yahoo.com]
Filippo DELLA ROCCA	V.P. Dole Research Team, Institute of Behavioural Sciences, Pisa, Italy, EU - [E-Mail: filippo.dellarocca@yahoo.it]
Maurice DEMATTEIS	CHU Grenoble-Alpes, Grenoble, France; INSERM UMR 987, Boulogne Billancourt, France; H6pital Cochin, Paris, France - [E-Mail: MDematteis@chu-grenoble.fr]
Mojca Zvezdana DERNOVSEK	Educational Institute Mountain, Ljubljana, Slovenia, EU - [E-Mail: mojca_dernovsek@t-2.net]
Alice DESCHENAU	GH Paul Guiraud, Villejuif, France, EU - [E-Mail: alice.deschenau@gh-paulguiraud.fr]
Suzan Ben EZRA	Department of Treatment and Rehabilitation, Israel Anti-Drug Authority, Jerusalem, Israel - [E-Mail: suzanbe@antidrugs.gov.il]
Ayman Mohsen FAREED	Mount Sinai Wellness Center, Dahlonga, GA, USA - [E-Mail: ayman.fareed@mtsinaiwellness.com]
Julia FEIT	Non-Public Health Care Center Sue Ryder Home, Bydgoszcz, Poland, EU - [E-Mail: j.feit@domsueryder.org.pl]
Loretta FINNEGAN	The College on Problems of Drug Dependence, Inc., Philadelphia, PA and Finnegan Consulting, Avalon, NJ, USA - [E-Mail: finnegan337@gmail.com]
Francina FONSECA	Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]
Edward Jacek GORZELAŃCZYK	Department of Theoretical Basis of Bio-Medical Sciences and Medical Informatics, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland, EU - [E-Mail: medsystem@medsystem.com.pl]
Aaron GREENBLATT	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: agreenbl@som.umaryland.edu]

Adam HAMED	Laboratory of Spatial Memory, Department of Cellular and Molecular Biology, Nencki Institute of Experimental Biology, Polish Academy of Sciences Warsaw, Poland - [E-Mail: a.hamed@nencki.gov.pl]
Martin HARALDSEN	Larvik Municipality - [E-Mail: martinharaldsen@outlook.com]
Dagmar HEDRICH	EMCDDA, Lisbon, Portugal - [E-Mail: Dagmar.Hedrich@emcdda.europa.eu]
Felicia HEIDEBRECHT	London South Bank University, London, UK - [E-Mail: felicias.research@gmx.de]
Shirley HERTZ-KEISAR	Psychiatry Resident, Ness-Ziona – Be'er Yaacov Mental Health Medical Center, Ness Ziona, Israel - [E-Mail: shirleykeisar@hotmail.com]
Duncan HILL	NHS Lanarkshire, UK - [E-Mail: Duncan.hill@lanarkshire.scot.nhs.uk]
Liljana IGNJATOVA	Centre for Prevention and Treatment of Drug Abuse and Addiction, Psychiatric Hospital Skopje, Skopje, Macedonia - [E-Mail: liljana.kiteva.ignjatov@medf.ukim.edu.mk]
Marion JOUHANNEAU	Unité Sanitaire - Maison d'Arrêt de Villeneuve les Maguelone, Villeneuve les Maguelone, France, EU - [E-Mail: f-meroueh@chu-montpellier.fr]
Alexander KANTCHELOV	The Kantchelov Clinic, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]
Karolina KARWOWSKA	Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, EU - [E-Mail: karolina.m.karwowska@gmail.com]
Andrej KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana & South Eastern European and Adriatic Addiction Treatment Network, Radomlje Homec, Slovenia, EU - [E-Mail: andrej.kastelic@guest.arnes.si]
Peter KASTNER	Ombudsman Institute Austria, Vienna, Austria - [E-Mail: peter.kastner@volksanwaltschaft.gv.at]
Riaz KHAN	Department of Mental Health and Psychiatry and Department of Primary Healthcare and Community Medicine, University Hospitals of Geneva, Switzerland - [E-Mail: Riaz.Khan@hcuge.ch]
Michał KIEŁBIŃSKI	Institute of Applied Psychology, Jagiellonian University, Krakow, Poland, EU - [E-Mail: michal.kielbinski@uj.edu.pl]
Christos KOUIMTSIDIS	Imperial College London, UK - [E-Mail: drckouimtsidis@hotmail.com]
Magdalena KOCOT-KĘPSKA	Department of Pain Research and Treatment, Medical College, Jagiellonian University, Krakow, Poland, EU - [E-Mail: makoco@wp.pl]
Wojciech LEPPERT	Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland, EU - [E-Mail: wojciechleppert@wp.pl]
Arturo G. LERNER	Lev-Hasharon Mental Health Medical Center, Pardessya, Israel & Sackler School Of Medicine, Tel Aviv University, Ramat Aviv, Israel - [E-Mail: artura@lev-hasharon.co.il]
Henry LOTHANE	Icahn School of Medicine at Mount Sinai, New York, NY, USA - [E-Mail: medsystem@medsystem.com.pl]
Barbara LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: barbara.lovrecic@nijz.si]
Mercedes LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@nijz.si]
Angelo G.I. MAREMMANI	Department of Psychiatry, North-Western Tuscany Region Local Health Unit, Versilian Zone, Viareggio, Italy, EU - [E-Mail: angelogimaremmanni@gmail.com]
Icro MAREMMANI	V.P. Dole Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmanni@med.unipi.it]
Rocio MARTIN-SANTOS	University of Barcelona, Spain - [E-Mail: rmsantos@clinic.ub.es]
Soraya MAYET	Humber NHS Foundation Trust, Hull, England, UK - [E-Mail: smayet@nhs.net]
Haim MELL	Yezreel Valley College, Afula, Israel - [E-Mail: mellhaim@012.net.il]
Fadi MEROUEH	Unité Sanitaire - Maison d'Arrêt de Villeneuve les Maguelone, Villeneuve les Maguelone, France, EU - [E-Mail: f-meroueh@chu-montpellier.fr]
Bodil MONWELL	Psychiatric clinic, County Hospital Ryhov/ Jönköping University, Sweden - [E-Mail: bodil.monwell@rjl.se]




Caroline NORMAN	Romão de Sousa Foundation, Lisbon, Portugal, EU - [E-Mail: <a href="mailto:tbc">tbc</a> ]
Heather A. OLSEN	Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA - [E-Mail: <a href="mailto:karin.mcbride@rmpdc.org">karin.mcbride@rmpdc.org</a> ]
Yngvild OLSEN	Johns Hopkins University School of Medicine; Maryland State Department of Health, Baltimore, MD, USA - [E-Mail: <a href="mailto:Yngvild.olsen1@maryland.gov">Yngvild.olsen1@maryland.gov</a> ]
Matteo PACINI	G. De Lisio Institute of Behavioural Sciences, Pisa, Italy - [E-Mail: <a href="mailto:paciland@virgilio.it">paciland@virgilio.it</a> ]
Mark PARRINO	American Association for the Treatment of Opioid dependence - AATOD, New York, NY, USA - [E-Mail: <a href="mailto:Mark.Parrino@aatod.org">Mark.Parrino@aatod.org</a> ]
Einat PELES	Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment and Research & Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel - [E-Mail: <a href="mailto:einatp@tlvmc.gov.il">einatp@tlvmc.gov.il</a> ]
Anna PRZEKLASA-MUSZYŃSKA	Department of Pain Research and Treatment, Jagiellonian University, Krakow, Poland, EU - [E-Mail: <a href="mailto:aprzemus@wp.pl">aprzemus@wp.pl</a> ]
Ryszard PRZEWŁOCKI	Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland, EU - [E-Mail: <a href="mailto:nfprzew@cyf-kr.edu.pl">nfprzew@cyf-kr.edu.pl</a> ]
Marc REISINGER	EUROPAD & WFTOD, Brussels, Belgium, EU - [E-Mail: <a href="mailto:m.reisinger@proximus.be">m.reisinger@proximus.be</a> ]
Pasqualina ROCCO	Servizio Dipendenze (Sero) U.L.S.S. n.2 Marca Trevigiana, Italy, EU - [E-Mail: <a href="mailto:pasqualina.rocco@aulss2.veneto.it">pasqualina.rocco@aulss2.veneto.it</a> ]
Carlos RONCERO	Psychiatric Service, University of Salamanca Health Care Complex, Salamanca, Spain, EU - [E-Mail: <a href="mailto:croncero@saludcastillayleon.es">croncero@saludcastillayleon.es</a> ]
Paola ROSKA	Department for the Treatment of Substance Abuse, Ministry of Health, Jerusalem, Israel - [E-Mail: <a href="mailto:paola.roska@MOH.GOV.IL">paola.roska@MOH.GOV.IL</a> ]
Luca ROVAI	Department of Psychiatry, Northern-West Tuscany Region Local Health Unit, Apuan Zone, Massa, Italy, EU - [E-Mail: <a href="mailto:lucarovai@yahoo.com">lucarovai@yahoo.com</a> ]
Anat SASON	Adelson clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel - [E-Mail: <a href="mailto:anatsas@tlvmc.gov.il">anatsas@tlvmc.gov.il</a> ]
Nusa SEGREC	University of Ljubljana, Faculty of Medicine, Department of Psychiatry, Ljubljana, Slovenia, EU - [E-Mail: <a href="mailto:nusa.segrec@psih-klinika.si">nusa.segrec@psih-klinika.si</a> ]
Omri SINAI	Lev Hasharon Medical Center, affiliated to Tel Aviv University, Tel Aviv, Israel - [E-Mail: <a href="mailto:omrisinai@yahoo.com">omrisinai@yahoo.com</a> , <a href="mailto:ofirliv@gmail.com">ofirliv@gmail.com</a> ]
Wojciech SOLECKI	Institute of Applied Psychology, Jagiellonian University, Krakow, Poland, EU - [E-Mail: <a href="mailto:wojciech.solecki@uj.edu.pl">wojciech.solecki@uj.edu.pl</a> ]
Lorenzo SOMAINI	Addiction Medicine Clinic (SerT) Cossano, Biella, Italy, EU - [E-mail: <a href="mailto:Lorenzo.Somaini@aslbi.piemonte.it">Lorenzo.Somaini@aslbi.piemonte.it</a> ]
Nestor SZERMAN	Department of Psychiatry, Hospital General Universitario Gregorio Marañón, Madrid, Spain, EU - [E-Mail: <a href="mailto:nszermanb@gmail.com">nszermanb@gmail.com</a> ]
Ilan TAL	Tal ambulatory Mental Health Center, Tel Aviv, Israel - [E-Mail: <a href="mailto:drtal@drtal.co.il">drtal@drtal.co.il</a> ]
Rok TAVCAR	University Psychiatric Hospital Ljubljana - [E-Mail: <a href="mailto:rok.tavcar@psih-klinika.si">rok.tavcar@psih-klinika.si</a> ]
Marta TORRENS	IMIM Hospital del Mar Medical Research Institute, Department Neurosciences Research Programme, University of Barcelona, Barcelona, Spain, EU - [E-Mail: <a href="mailto:mtorrens@parcdesalutmar.cat">mtorrens@parcdesalutmar.cat</a> ]
Didier TOUZEAU	Clinique Liberté, Bagneux, France, EU - [E-Mail: <a href="mailto:didier.touzeau@gmail.com">didier.touzeau@gmail.com</a> ]
Albrecht ULMER	General Practitioner, Stuttgart, Germany, EU - [E-Mail: <a href="mailto:albrecht.ulmer@gmx.de">albrecht.ulmer@gmx.de</a> ]
Eric WEINTRAUB	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: <a href="mailto:eweindra@som.umaryland.edu">eweindra@som.umaryland.edu</a> ]
Gabrielle Katrine WELLE-STRAND	SERAF - Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway - [E-Mail: <a href="mailto:Gabrielle.Katrine.Welle-Strand@helseidir.no">Gabrielle.Katrine.Welle-Strand@helseidir.no</a> ]
Christopher WELSH	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: <a href="mailto:cwelsh@som.umaryland.edu">cwelsh@som.umaryland.edu</a> ]

Jamie WILLIAMS      Healing Therapy Services, Providence, Rhode Island, USA - [E-Mail: jfwww1@juno.com ]  
Jolanta B. ZAWILSKA      Department of Pharmacodynamics Medical University of Lodz, Poland, EU - [E-Mail:  
medsystem@medsystem.com.pl]

[Redacted content]





# EUROPAD2018Krakow

European Opiate Addiction Treatment Association | Congress



## European Union of Medical Specialists

EACCME - European Accreditation Council for Continuing Medical Education

Institution of the UEMS

Rue de l'Industrie 24, B-1040, Brussels

T: +32 2 649 5164 | F: +32 2 640 37 30 | E: [accreditation@uems.eu](mailto:accreditation@uems.eu)

The 13th EUROPAD Conference was granted xx European CME credits (ECMEC)  
by the European Accreditation Council for Continuing Medical Education (EACCME)

Platinum sponsors



**MOLTENI**  
FARMACEUTICI